- Home
- LAW vs DRUG Comparison
LAW vs DRUG Comparison
Compare LAW & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAW
- DRUG
- Stock Information
- Founded
- LAW 2013
- DRUG 2019
- Country
- LAW United States
- DRUG United States
- Employees
- LAW N/A
- DRUG N/A
- Industry
- LAW Computer Software: Prepackaged Software
- DRUG Pharmaceuticals and Biotechnology
- Sector
- LAW Technology
- DRUG Health Care
- Exchange
- LAW Nasdaq
- DRUG Nasdaq
- Market Cap
- LAW N/A
- DRUG 233.2M
- IPO Year
- LAW 2021
- DRUG N/A
- Fundamental
- Price
- LAW $3.69
- DRUG $32.62
- Analyst Decision
- LAW Hold
- DRUG Strong Buy
- Analyst Count
- LAW 3
- DRUG 4
- Target Price
- LAW $6.17
- DRUG $84.33
- AVG Volume (30 Days)
- LAW 94.5K
- DRUG 30.8K
- Earning Date
- LAW 05-08-2025
- DRUG 05-16-2025
- Dividend Yield
- LAW N/A
- DRUG N/A
- EPS Growth
- LAW N/A
- DRUG N/A
- EPS
- LAW N/A
- DRUG N/A
- Revenue
- LAW $144,841,000.00
- DRUG N/A
- Revenue This Year
- LAW $5.43
- DRUG N/A
- Revenue Next Year
- LAW $5.64
- DRUG N/A
- P/E Ratio
- LAW N/A
- DRUG N/A
- Revenue Growth
- LAW 4.89
- DRUG N/A
- 52 Week Low
- LAW $3.31
- DRUG $0.93
- 52 Week High
- LAW $8.20
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- LAW 43.04
- DRUG 49.10
- Support Level
- LAW $3.31
- DRUG $31.10
- Resistance Level
- LAW $3.68
- DRUG $35.94
- Average True Range (ATR)
- LAW 0.22
- DRUG 2.46
- MACD
- LAW 0.04
- DRUG 0.38
- Stochastic Oscillator
- LAW 48.10
- DRUG 66.76
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.